Press Releases
Merck & Co Inc Final overall survival data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma To Be Presented at 2016 ASCO Annual Meeting
Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued...
Press Releases
GlaxoSmithKline presents new data from Breo Ellipta SUMMIT study in patients with COPD at ATS Conference
GlaxoSmithKline and Innoviva, Inc announced that GlaxoSmithKline plc (GSK) presented new data at the American Thoracic Society (ATS) Conference from two pre-specified analyses from the...
Press Releases
GlaxoSmithKline presents positive data for Anoro Ellipta in COPD patients who remained symptomatic on tiotropium
GlaxoSmithKline and Innoviva Inc announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy and safety of Anoro®...
Press Releases
Amgen Inc Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients
New Analysis From Phase 3 Trial of Kyprolis® (Carfilzomib) Combination Treatment in Relapsed Multiple Myeloma Patients With Early Disease ProgressionPhase 1/3 MASTERKEY-265 Study Abstracts Present...
Press Releases
AstraZeneca reports the positive Top-Line Results from the Benralizumab Phase III Programme in Severe Asthma
Kyowa Hakko Kirin Co Ltd announced that AstraZeneca obtained the positive top-line results that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well...
Press Releases
FDA approves For Eisais Anticancer Agent Lenvima In Combination With Everolimus as Treatment For advanced Renal Cell Carcinoma
Eisai Co Ltd announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication...
Press Releases
AstraZeneca reports positive results from benralizumab phase III programme
AstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.